RK

Ranjan Kumar

Active Director Director DIN 10709658
DIN 10709658 First appointment Jul 2024 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2024
Shareholding value •••• Premium profile

About Ranjan Kumar

Data last updated:

Ranjan Kumar is a Director at Promethus Pharma Private Limited (since 2024). The company operates in Chemicals. Promethus Pharma Private Limited reported revenue of ₹6.2 Lakh (FY 2023).

DIN 10709658
Primary Designation Director
Industry Chemicals
First Appointment 17 Jul 2024
Oldest Company Age 4 yrs
Largest company Promethus Pharma Private Limited · ₹6.2 Lakh (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Promethus Pharma Private Limited U24100BR2022PTC059655
Director17 Jul 20242022₹6.2 Lakh (FY 2023)Active

Board colleagues of Ranjan Kumar

Directorship timeline

Open interactive timeline →
Promethus Pharma Private Limited
Premium access

Shareholding and investment profile for Ranjan Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ranjan Kumar

Ranjan Kumar currently holds 1 directorship: Promethus Pharma Private Limited (Director, since 17 Jul 2024, revenue ₹6.2 Lakh (FY 2023)).

Ranjan Kumar was first appointed on 17 Jul 2024 as Director at Promethus Pharma Private Limited.

The current boards of Ranjan Kumar's companies include Nirmala Verma (Promethus Pharma Private Limited), Ravikant Kumar (Promethus Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available